- $18 BnWorld market, 2023
- $23.5 BnProjected, 2033
- 2.7%Growth a year (CAGR)
- 2,467Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$7.6 Bn
0.7% a year · 42% of the world -
2
China
$1.4 Bn
4.2% a year · 8% of the world -
3
Canada
$1.4 Bn
2.7% a year · 8% of the world -
4
Japan
$1.1 Bn
3.2% a year · 6.2% of the world -
5
Germany
$659 Mn
0.9% a year · 3.7% of the world -
6
France
$495 Mn
1.7% a year · 2.8% of the world -
7
UK
$468 Mn
0.7% a year · 2.6% of the world -
8
Brazil
$450 Mn
3.7% a year · 2.5% of the world -
9
Italy
$432 Mn
2.2% a year · 2.4% of the world -
10
Ecuador
$360 Mn
3.3% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
Spain
Hong KongAnti-Depressants Drugs by country and region
India
Saudi Arabia
Mexico
Australia
South Africa
UAE
Egypt
Philippines
Malaysia
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 22,373 papers since 2021
- GLP-1 Receptor Agonists Use in Patients With Prior Psychotropic Treatment: A Nationwide Cohort Study. Diabetes, obesity & metabolism, 2026
- US real-world data: sleep and mental health burden in chronic spontaneous urticaria. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2026
- Ketamine for Co-occurring Chronic Pain and Depression: A Scoping Review fing the Dual-Outcome Evidence Gap and Its Treatment and Research Implications. The journal of pain, 2026
- The effects of pulse dosing on the clinical trajectory of rTMS and iTBS: A re-analysis of two sham-controlled studies in major depressive disorder. Journal of psychiatric research, 2026
- Current perspectives in the pharmacological treatment of gambling disorder: psychedelics and beyond. Expert opinion on pharmacotherapy, 2026
Compare Anti-Depressants Drugs side by side
Key companies in Anti-Depressants Drugs
Johnson & Johnson
Pfizer Inc.
Eli Lilly and Company:
GlaxoSmithKline plc
Abbott Laboratories
AstraZeneca plc
Merck & Co., Inc.
Novartis AG
Bristol-Myers Squibb Company
Sanofi S.A.
Quick answers
How big is the Anti-Depressants Drugs market?
The world Anti-Depressants Drugs market was worth about $18 Bn in 2023 and is projected to reach $23.5 Bn by 2033, growing 2.7% a year (CAGR).
Which country has the largest Anti-Depressants Drugs market?
The US is the largest of the 24 countries we cover, at $7.6 Bn in 2023. India grows fastest, at 5.7% a year.
How many clinical trials are running in Anti-Depressants Drugs?
ClinicalTrials.gov lists 2,467 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Anti-Depressants Drugs?
PubMed lists about 22,373 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.